The shrimp farming industry is receiving increasing attention globally. However, extending the frontiers of the industry has been a challenge as high stocking density often increases susceptibility to diseases and compromises shrimp quality. There has been a huge adoption of bacterial‐derived additives in recent decades, particularly in Asia. Accumulating evidence demonstrates the modulatory effect of these functional additives on the animal gut microbiota composition, thus making them potential alternatives to antibiotics in controlling infectious diseases, such as acute hepatopancreatic necrosis disease (AHPND). These functional additives could be introduced in various forms, such as probiotics, synbiotics, paraprobiotics, and postbiotics. This article aims to critically review previous studies that investigated the effects of these bacterial derivatives, particularly on shrimp species. The surge of research in recent years indirectly attested to the immense potentialities of these functional additives. Generally, the introduction of bacterial derivatives not only helped in disease control but also demonstrated encouraging outcomes, including better survival rate, immune enhancement, and growth promotion effects. It is interesting to note that the effectiveness of probiotics extended beyond the viability of the bacteria, thus leading to concepts such as paraprobiotics and postbiotics. Although this is a relatively new research area with limited information, this review aims to consolidate available data and provide a comprehensive overview of the state of the art of this research arena. The challenges in each research domain were also discussed towards the end of this review to provide insights into potential future research niches.

As feed accounts for a significant proportion of a farm’s expenditure, animal nutrition is one of the key profit determinants. Attributed to the size-dependent market value, enhancing shrimps' growth is essential to maximize profit. Despite not being the best option, antibiotics are often used as growth-promoting agents in farming. Although this trend is less explicit in aquaculture, increasing production yield is paramount, especially when intensive aquafarming compromises animal growth and increases disease prevalence. However, the environmental and clinical pitfalls of indiscriminate antibiotic usage are surfacing. Fortunately, increasing evidence demonstrated probiotics as a safer, more sustainable, and environmental-friendly substitute for antibiotics. Nonetheless, most studies are observational, and the growth-promotion mechanisms of these agents are yet to be elucidated. In this light, this review aims to decipher the growth promotion mechanisms of probiotics in shrimps based on the primary works conducted. Evidently, probiotic treatment modulates the gut microbiome composition. The growth promotion effect of probiotics is partly mediated through the production of bioactive compounds such as short-chain fatty acids, vitamins, and polyamines. Besides, elevated digestive enzyme activities following the introduction of probiotics may help enhance digestibility and utilization. Histological changes at the hepatopancreas and intestine were evident. Furthermore, probiotics may reinforce the protective mechanisms in the gut and strengthen immune function. Treated shrimps demonstrate better appetite and exhibit superior metabolic and growth-related genes profile. Contrasting these recognized mechanisms with antibiotics helps construct the initial framework for designing high-quality probiotics for growth enhancement in farmed animals.

The increasing prevalence of resistance in carbapenems is an escalating concern as carbapenems are reserved as last-line antibiotics. Although indiscriminate antibiotic usage is considered the primary cause for resistance development, increasing evidence revealed that inconsequential strains without any direct clinical relevance to carbapenem usage are harboring carbapenemase genes. This phenomenon indirectly implies that environmental microbial populations could be the ‘hidden vectors’ propelling carbapenem resistance. This work aims to explore the carbapenem-resistance profile of Vibrio species across diverse settings. This review then proceeds to identify the different factors contributing to the dissemination of the resistance traits and defines the transmission pathways of carbapenem resistance. Deciphering the mechanisms for carbapenem resistance acquisition could help design better prevention strategies to curb the progression of antimicrobial resistance development. To better understand this vast reservoir selecting for carbapenem resistance in non-clinical settings, Vibrio species is also prospected as one of the potential indicator strains for carbapenem resistance in the environment.

The past two years have been a turmoil for the world and people due to the COVID-19 pandemic. It was the first time in history that the whole world was on a standstill after many countries-imposed movement control orders and restrictions. Many innocent lives were lost, and the spread of infection is still ongoing. Pharmaceutical companies raced against the time to develop vaccines, believing that it would be sufficient to control COVID-19. Nevertheless, the recent emergence of the SARS-CoV-2 variant as Omicron has become a global concern. This new variant of concern (VOC) spreads faster than other VOC strains and poses a high risk, mounting fears of new waves of infections in many countries, including Malaysia. This review discussed characteristics of Omicron, the emergence of Omicron cases in Malaysia, and preventive measures to control the spread of COVID-19.